LCTX
BEARISHAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
No Graham Number available due to lack of earnings; valuation is purely speculative.
- P/S of 26.70 is excessive
- P/B of 8.52 indicates high premium over book
- PEG of 10.64 suggests overvaluation relative to growth
Growth is present in top-line revenue but not translating to bottom-line stability.
- 130.4% Revenue growth
- Strong analyst price targets
- Year-over-year EPS growth of -550%
- Consistent earnings misses
Historical performance is characterized by volatility and consistent losses.
- Recent 1-year price recovery
- 5-year change is negative (-41.4%)
- Long history of quarterly losses
High cash reserves are the only factor preventing immediate insolvency.
- Low Debt/Equity
- High Current Ratio
- Piotroski F-Score 1/9
- Negative ROE (-105.3%)
- Negative Gross Margin
Typical for early-stage biotech; not a priority.
- No dividend paid
- No history of payouts
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for LCTX and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
LCTX
Lineage Cell Therapeutics, Inc.
Primary
|
-41.4% | +14.7% | +239.1% | -9.8% | +6.1% | -4.9% |
|
XFOR
X4 Pharmaceuticals, Inc.
Peer
|
-98.4% | -90.0% | -29.0% | +38.5% | +12.0% | +3.4% |
|
NRC
NRC Health
Peer
|
-61.4% | -56.9% | +63.3% | +52.5% | -0.1% | -5.9% |
|
AKBA
Akebia Therapeutics, Inc.
Peer
|
-59.4% | +113.8% | -13.6% | -50.5% | -5.8% | +15.0% |
|
CYH
Community Health Systems, Inc.
Peer
|
-74.0% | -54.0% | -5.6% | -33.7% | -7.5% | -13.9% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Quarterly Earnings History
EPS performance vs analyst estimates
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
LCTX
Lineage Cell Therapeutics, Inc.
|
BEARISH | $388.58M | - | -105.3% | -% | $1.56 | |
|
XFOR
X4 Pharmaceuticals, Inc.
|
BEARISH | $389.14M | - | -76.0% | -225.6% | $4.28 | Compare |
|
NRC
NRC Health
|
BEARISH | $389.19M | 34.22 | 51.2% | 8.4% | $17.11 | Compare |
|
AKBA
Akebia Therapeutics, Inc.
|
BEARISH | $391.1M | - | -% | -2.3% | $1.46 | Compare |
|
CYH
Community Health Systems, Inc.
|
BEARISH | $383.29M | 0.79 | -% | 3.8% | $2.72 | Compare |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-12 | CULLEY BRIAN M | Chief Executive Officer | Purchase | 15,000 | $24,375 |
| 2026-02-11 | CULLEY BRIAN M | Chief Executive Officer | Stock Award | 31,250 | - |
| 2026-02-11 | SAMUEL GEORGE A. III | General Counsel | Stock Award | 6,075 | - |
| 2025-12-19 | CULLEY BRIAN M | Chief Executive Officer | Stock Award | 8,925 | - |
| 2025-12-19 | SAMUEL GEORGE A. III | General Counsel | Stock Award | 1,735 | - |
SEC Filings
Recent regulatory filings from the SEC EDGAR database
LCTX filed its 10-K on March 5, 2026, which includes standard sections for risk factors, management's discussion and analysis, and financial statements. The provided excerpts consist only of the filing's table of contents and do not contain specific financial highlights or detailed risk disclosures.
For the nine months ended September 30, 2025, LCTX reported a 20% increase in total revenues to $7.9 million, driven primarily by a 30% rise in collaboration revenues. The company expanded its preclinical pipeline through a new research collaboration with WDI, which provides up to $12 million over three years to advance the development of ReSonance (ANP1). Financial risks include a significant quarterly decline in royalty and license revenues, which fell 65% compared to the prior year.
LCTX reported total revenues of $4.267 million for the six months ended June 30, 2025, a 50% increase over the prior year driven primarily by a 66% rise in collaboration revenues. The company is advancing a pipeline of allogeneic cell therapies, including OpRegen in Phase 2a and OPC1 in Phase 1b clinical trials. Financial stability remains dependent on collaboration agreements and the inherent risks associated with clinical-stage development of its neurology and ophthalmic programs.
Wall Street Analysts
Professional analyst ratings and price targets
Past News Coverage
Recent headlines mentioning LCTX from our newsroom.